Table 2.
Laboratory findings prior to the initiation of the combination treatment with sofosbuvir and ribavirin in case 2
| Item | Value | Item | Value |
|---|---|---|---|
| AST | 10 IU/l | WBC | 2,900/μl |
| ALT | 17 IU/l | RBC | 372 × 104/μl |
| LDH | 164 IU/l | hemoglobin | 10.8 g/dl |
| ALP | 265 IU/l | hematocrit | 33.4% |
| γ-GTP | 53 IU/l | platelets | 4.7 × 104/μl |
| T.BIL | 0.7 mg/dl | PT | 100% |
| D.BIL | 0.1 mg/dl | PT-INR | 1.03 |
| TP | 6.6 g/dl | anti-HCV | positive |
| Alb | 3.7 g/dl | HCV RNA | 7.0 log IU/ml |
| T.CHO | 152 mg/dl | HCV genotype | 2b |
| UA | 6.9 mg/dl | HBsAg | negative |
| UN | 26 mg/dl | anti-HBs | negative |
| Cre | 1.10 mg/dl | HBV DNA | negative |
| eGFR | 53.5 ml/min/1.73 m2 | anti-HIV | negative |
LDH = Lactate dehydrogenase; ALP = alkaline phosphatase; γ-GTP = γ-glutamyltransferase; T.BIL = total bilirubin; D.BIL = direct bilirubin; TP = total protein; Alb = albumin; T.CHO = total cholesterol; UA = uric acid; UN = urea nitrogen; Cre = creatinine; WBC = white blood cell count; RBC = red blood cell count; PT = prothrombin time; PT-INR = PT international normalized ratio; anti-HCV = anti-HCV antibody; HBsAg = hepatitis B virus surface antigen; anti-HBs = anti-hepatitis B virus surface antibody; anti-HIV = anti-human immunodeficiency virus antibody.